When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself.
Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform. By looking at an individual person’s epigenetics, the company can provide invaluable insight into the impact of their lifestyle, behavior, and environment on heart disease risk. Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution.
Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the mechanism that controls this reading process, influenced by factors such as diet, exercise, stress, and exposure to pollutants.
For business leaders and technology innovators, this represents a paradigm shift in how cardiovascular risk is assessed and managed. Traditional risk assessments rely heavily on static genetic markers and family history, which can miss the dynamic influence of a person’s daily choices and environment. Cardio Diagnostics’ approach offers a more nuanced and actionable view, potentially enabling earlier intervention and personalized prevention strategies.
The implications for the healthcare industry are significant. If epigenetics-based testing becomes widely adopted, it could reduce the burden of heart disease—the leading cause of death globally—by identifying at-risk individuals sooner and guiding them toward lifestyle modifications or treatments that address the root causes. For employers and insurers, this could translate into lower healthcare costs and improved workforce health. For patients, it offers a clearer path to proactive heart health management.
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. As with any forward-looking statements, investors are advised to review the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
